Aclaris Therapeutics Validates ATI-052 Potency, Reaffirms Key Clinical Timelines — Aclaris Therapeutics, Inc.

Event summary

Phase 1a trial of ATI-052 shows favorable safety profile and potential for quarterly dosing
Top line results from Phase 1b POC trials of ATI-052 in asthma and atopic dermatitis expected in H2 2026
$40.2M raised via ATM offering to extend cash runway through end of 2028
Phase 2b trial for modzatinib (ATI-2138) in lichen planus planned for Q4 2026

The big picture

Aclaris Therapeutics is advancing its immuno-inflammatory disease pipeline with multiple clinical readouts expected by year-end. The company's focus on bispecific antibodies and kinase inhibitors positions it in a competitive biotech landscape where differentiation through potency and dosing flexibility is key. With $170.6M in cash as of Q2 2026, Aclaris has extended its runway to support development through 2028, but must deliver on clinical milestones to maintain investor confidence.

What we're watching

Clinical Validation: Whether ATI-052's best-in-class potency will translate into successful Phase 1b POC trials in asthma and atopic dermatitis.
Execution Risk: The pace at which Aclaris can initiate multiple Phase 2b trials while maintaining financial discipline.
Market Differentiation: How ATI-9494's potency and selectivity will position it against competitors like soquelitinib (CPI-818).